# EDGAR Filing Document

**Accession Number:** 0001348911
**File Stem:** 0001306267-26-000002
**Filing Date:** 2026-6
**Character Count:** 9655
**Document Hash:** 38c2128a8eeefaa0512b4b6d9d717e7b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001306267-26-000002.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0001306267-26-000002

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260611

**FILED AS OF DATE**: 20260611

**DATE AS OF CHANGE**: 20260611

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Unkart Edward W
- **CENTRAL INDEX KEY:** 0001306267

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36830
- **FILM NUMBER:** 261083469

**MAIL ADDRESS:**
- **STREET 1:** C/O KALVISTA PHARMACEUTICALS, INC.
- **STREET 2:** 55 CAMBRIDGE PARKWAY, SUITE 901E
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KalVista Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001348911
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 200915291
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CROSSING BOULEVARD
- **CITY:** FRAMINGHAM
- **STATE:** MA
- **ZIP:** 01702
- **BUSINESS PHONE:** (857) 999-0075

**MAIL ADDRESS:**
- **STREET 1:** 200 CROSSING BOULEVARD
- **CITY:** FRAMINGHAM
- **STATE:** MA
- **ZIP:** 01702

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carbylan Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20140916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carbylan Biosurgery, Inc
- **DATE OF NAME CHANGE:** 20130102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carbylan Biosurgery Inc
- **DATE OF NAME CHANGE:** 20060105

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Unkart Edward W<br><sub>(Last) (First) (Middle)</sub><br>C/O KALVISTA PHARMACEUTICALS, INC.<br>200 CROSSING BOULEVARD<br><sub>(Street)</sub><br>FRAMINGHAM, MA 01702<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-06-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>KalVista Pharmaceuticals, Inc. [ KALV ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $7.88 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 12000 | <sup>(2)</sup> | 2027-03-22 | Common Stock | 12000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $6.71 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 6000 | <sup>(2)</sup> | 2027-09-26 | Common Stock | 6000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $17.45 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 10000 | <sup>(2)</sup> | 2031-09-29 | Common Stock | 10000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $22.65 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 7000 | <sup>(2)</sup> | 2028-10-02 | Common Stock | 7000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $11.21 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 7000 | <sup>(2)</sup> | 2029-10-01 | Common Stock | 7000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $12.88 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 7000 | <sup>(2)</sup> | 2030-09-30 | Common Stock | 7000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $4.53 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 10000 | <sup>(2)</sup> | 2032-10-12 | Common Stock | 10000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $10.08 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 10000 | <sup>(2)</sup> | 2033-09-25 | Common Stock | 10000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $11.54 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 10000 | <sup>(2)</sup> | 2034-10-02 | Common Stock | 10000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $12.05 | 2026-06-11 |  | D<sup>(1)</sup> |  |  | 30000 | <sup>(4)</sup> | 2035-09-30 | Common Stock | 30000 | <sup>(3)</sup> | 0 | D |  |

---

### Footnotes:

(1) The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger").

(2) The option is fully vested.

(3) Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof.

(4) The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

**Signature:** /s/ Benjamin L. Palleiko, Attorney-in-Fact  
**Date:** 2026-06-11

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**